Third strike for Wockhardt as API facility hit with US import alert

By Dan Stanton contact

- Last updated on GMT

Image: iStock/suvisuni
Image: iStock/suvisuni

Related tags: Import alert, Food and drug administration, Pharmaceutical drug

The US FDA has banned products from a third Indian manufacturing plant operated by Wockhardt.

The plant located in Ankleshwar, in the Gujarat region of India makes bulk active pharmaceutical ingredients (APIs) but a US Food and Drug Administration (FDA) import alert issued on Friday means the products are now banned from being exported to the US.

In a filing to the Bombay Stock Exchange, Wockhardt acknowledged the US FDA has updated the Import Alert 66-40 to include its API unit and said it was awaiting official communication from the US FDA on this matter.

The FDA’s actions come following an inspection last year which resulted in a Form 483, highlighting a number of manufacturing concerns.

“The Company has already initiated required steps to address the concerns raised by USFDA and is putting all efforts to resolve the matter,”​ Wockhardt added.

The API plant is the third Wockhardt facility to be banned from sending products to the US.

The company’s Waluj​ and Chikalthana​ finished formulation plants – both in Aurangabad, Maharashtra – were hit with an import alert, with products made at the sites placed under Detention Without Physical Examination (DWPE) by the FDA, in 2013.

Shares in Wockhardt fell by nearly 14% Monday, following the FDA’s announcement.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars